 "Sun Pharma regains Rs 1 trillion m-cap after surging 38% in four days")
Shares of Sun Pharmaceuticals Industries were trading higher for the fourth straight day, up 8.5 per cent to Rs 474 on the BSE on Thursday on expectation of improvement in the company's outlook.
The drug firm's stock was trading close to its 52-week high of Rs 480, touched on April 10, 2019. In the past four days, it has rallied 38 per cent, as compared to 10 per cent rise in the S&P BSE Sensex and 23 per cent up move in S&P BSE Healthcare index.
Sun Pharma has regained the market-capitalisation of Rs 1-trillion after a sharp rally in its stock price. At 01:20 pm, the company had the market-capitalisation of Rs 1.12-trillion, the BSE data shows.
The trading volumes on the counter have nearly doubled with a combined 30 million shares changing hands on the counter on the NSE and BSE so far.
Most analysts believe Indian pharma sector’s has been relatively resilient to the Covid-19 disruption, favorable currency tailwinds and stable outlook for India and US business.
“The pharmaceutical companies are doing their best by managing the key medicine supplies to the market as demand remain strong being under essential commodities segment. However, the lockdown scenario has cropped several unprecedented challenges. These challenges have led to lower capacity utilisation at most of the plant levels,” analysts at Centrum Broking said in sector update.
The brokerage firm remains confident on the strong demand scenario from both domestic and export markets. Also, believe that these disruptions would not be meaningful from full year earnings perspective as the benefits of weaker currency could bridge the gap. It recommends ‘buy’ rating on the stock with price target of Rs 575 per share.
“Sun Pharma has invested significantly in building specialty pipeline and the costs are reflected in P&L. With most assets now commercialised, we expect margins to improve as the launches gain market share,” analysts at HDFC Securities said in sector update.
The brokerage firm believes the pharma sector is poised for 15 per cent earnings CAGR over the next two years. The earnings revision cycle is nearing bottom and there is limited scope for valuations to deteriorate, it said.
The drug firm's stock was trading close to its 52-week high of Rs 480, touched on April 10, 2019. In the past four days, it has rallied 38 per cent, as compared to 10 per cent rise in the S&P BSE Sensex and 23 per cent up move in S&P BSE Healthcare index.
Sun Pharma has regained the market-capitalisation of Rs 1-trillion after a sharp rally in its stock price. At 01:20 pm, the company had the market-capitalisation of Rs 1.12-trillion, the BSE data shows.
The trading volumes on the counter have nearly doubled with a combined 30 million shares changing hands on the counter on the NSE and BSE so far.
Most analysts believe Indian pharma sector’s has been relatively resilient to the Covid-19 disruption, favorable currency tailwinds and stable outlook for India and US business.
“The pharmaceutical companies are doing their best by managing the key medicine supplies to the market as demand remain strong being under essential commodities segment. However, the lockdown scenario has cropped several unprecedented challenges. These challenges have led to lower capacity utilisation at most of the plant levels,” analysts at Centrum Broking said in sector update.
The brokerage firm remains confident on the strong demand scenario from both domestic and export markets. Also, believe that these disruptions would not be meaningful from full year earnings perspective as the benefits of weaker currency could bridge the gap. It recommends ‘buy’ rating on the stock with price target of Rs 575 per share.
“Sun Pharma has invested significantly in building specialty pipeline and the costs are reflected in P&L. With most assets now commercialised, we expect margins to improve as the launches gain market share,” analysts at HDFC Securities said in sector update.
The brokerage firm believes the pharma sector is poised for 15 per cent earnings CAGR over the next two years. The earnings revision cycle is nearing bottom and there is limited scope for valuations to deteriorate, it said.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%